ARC-20: Casdatifan for Patients With Previously Treated ccRCC

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Brad McGregor, MD, of Dana-Farber Cancer Institute, explains the safety, efficacy, and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study of casdatifan monotherapy in patients with previously treated clear cell renal cell carcinoma.

He shares whether there are specific subgroup populations that are more likely to benefit from casdatifan treatment, as well as whether he anticipates casdatifan providing synergistic effects in a combination with other agents.